These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21394210)

  • 1. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors.
    Clegg NJ; Couto SS; Wongvipat J; Hieronymus H; Carver BS; Taylor BS; Ellwood-Yen K; Gerald WL; Sander C; Sawyers CL
    PLoS One; 2011 Mar; 6(3):e17449. PubMed ID: 21394210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.
    Yang G; Goltsov AA; Ren C; Kurosaka S; Edamura K; Logothetis R; DeMayo FJ; Troncoso P; Blando J; DiGiovanni J; Thompson TC
    Mol Cancer Res; 2012 Feb; 10(2):218-29. PubMed ID: 22144662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
    Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
    PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
    Nandana S; Ellwood-Yen K; Sawyers C; Wills M; Weidow B; Case T; Vasioukhin V; Matusik R
    Prostate; 2010 May; 70(6):591-600. PubMed ID: 19938013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.
    Kladney RD; Cardiff RD; Kwiatkowski DJ; Chiang GG; Weber JD; Arbeit JM; Lu ZH
    Cancer Res; 2010 Nov; 70(21):8937-47. PubMed ID: 20940396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.
    Majumder PK; Febbo PG; Bikoff R; Berger R; Xue Q; McMahon LM; Manola J; Brugarolas J; McDonnell TJ; Golub TR; Loda M; Lane HA; Sellers WR
    Nat Med; 2004 Jun; 10(6):594-601. PubMed ID: 15156201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions.
    Benavides F; Blando J; Perez CJ; Garg R; Conti CJ; DiGiovanni J; Kazanietz MG
    Cell Cycle; 2011 Jan; 10(2):268-77. PubMed ID: 21224724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression.
    Ko YH; Miyake H; Behnsawy HM; Cheon J; Fujisawa M
    Urol Int; 2014; 93(2):146-51. PubMed ID: 24556942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.
    Majumder PK; Yeh JJ; George DJ; Febbo PG; Kum J; Xue Q; Bikoff R; Ma H; Kantoff PW; Golub TR; Loda M; Sellers WR
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7841-6. PubMed ID: 12799464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
    Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
    PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
    Lee SH; Poulogiannis G; Pyne S; Jia S; Zou L; Signoretti S; Loda M; Cantley LC; Roberts TM
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11002-7. PubMed ID: 20534477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
    Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
    Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer.
    Floc'h N; Abate-Shen C
    Oncotarget; 2012 Dec; 3(12):1483-4. PubMed ID: 23242005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.